Clinical Trial Update: A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating lorlatinib in patients with ROS1-positive advanced or metastatic non-small cell lung cancer. The study is currently active but…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lorlatinib (Lorbrena) (lorlatinib)

Snippet

Sponsor: CStone Pharmaceuticals | Conditions: Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING